Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. For advanced HCC, sorafenib was considered the standard of care for more than ten years. Recently the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either im...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Ankit, Chitturi, Shivakumar, Peters, Geoffrey, Yip, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473489/
https://www.ncbi.nlm.nih.gov/pubmed/34630880
http://dx.doi.org/10.4254/wjh.v13.i9.1132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473489/
https://www.ncbi.nlm.nih.gov/pubmed/34630880
http://dx.doi.org/10.4254/wjh.v13.i9.1132

Ejemplares similares